We found that the numbers of activated MDSCs (CD11b+Gr‐1+) and Tregs (CD4+CD25+Foxp3+) among the tumor‐infiltrating lymphocytes in the MAP treatment group were significantly reduced (Figure S4F–I, Supporting Information). This evidence concerns the gene CD4 and neoplasm.